The study findings demonstrate that mice treated with Apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with Gossypol. The results support Coronado Biosciences’ continued development of its lead candidate, CNDO103, as a cancer treatment.
RJ Tesi, president and CEO of Coronado Biosciences, said: “We plan to perform IND-enabling preclinical studies for Apogossypol, CNDO103, in the first half of 2008. If the toxicity profile in animals approximates what was shown in this work, we plan to file an IND in late 2008.”